Абстрактный

Serum levels of advanced glycation end products in type II diabetic patients with acute cerebral infarction

Hao Ju, Qingshi Zhao, Wei Li, Haiyan Liu, Yan Gao, Lin Yi, Hongyan Wang, Zhaohui Wang, Chuan Liu, Fanhua Meng, Haiping Li, Ligang Jiang

Background: Advanced glycation end products (AGEs) are reported to be associated with diabetic vascular complications. However, the role of AGEs in the pathogenesis of cerebral thrombosis remains unclear. This study aimed to investigate the relationship between advanced glycation end products (AGEs) generation and pathogenesis of cerebral thrombosis.

Methods: 100 patients with cerebral thrombosis were recruited and 50 healthy controlled individuals were served as a control group. Enzyme Linked Immunosorbent Assay (ELISA) was applied for measuring serum AGEs level. The condition of carotid intima was examined by carotid ultrasonography. Serum AGEs levels were compared among patients with certain conditions of carotid atherosclerosis.

Results: AGEs levels in carotid plaque or thickening groups showed significant difference compared with those in control group. Carotid plaque patients showed remarkably different AGEs levels compared to thickening patients. AGEs levels were significantly elevated with higher severity of carotid plaque. Moderate or severe stenosis patients, or blocked group showed significantly different AGEs compared to mild stenosis group. Severe stenosis or blockade group showed remarkably different AGEs compared with moderate stenosis patients. In addition, severe stenosis group had statistically different AGEs compared with blockade group.

Conclusion: AGEs level is correlated with pathogenesis of cerebral thrombosis and they are further elevated with aggravation of carotid atherosclerosis in patients, suggesting they might be used as a biomarker to evaluate the severity of atherosclerosis.